Article Details

Shot in the arm for GSK as £1.2bn respiratory jab Arexvy is approved for a younger age group

Retrieved on: 2024-06-10 21:06:46

Tags for this article:

Click the tags to see associated articles and topics

Shot in the arm for GSK as £1.2bn respiratory jab Arexvy is approved for a younger age group. View article details on hiswai:

Summary

The article discusses GSK's recent FDA approval for the Arexvy respiratory jab to be used in younger patients, highlighting its competitive stance against Pfizer in the vaccine market, which includes COVID-19 vaccines. This development ties in investments and deployment aspects.

Article found on: www.thisismoney.co.uk

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up